[177Lu]-Dota0-Tyr3-Octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma

Current Radiopharmaceuticals - United Arab Emirates
doi 10.2174/1874471011003010029
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Bentham Science Publishers Ltd.

Related search

Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors With [177Lu-DOTA0,Tyr3]Octreotate

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2015English

Effects of Therapy With [177Lu-DOTA0,Tyr3]octreotate on Endocrine Function

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2009English

P2.12-03 Phase I/Ii Trial of 177Lu-Dota0-Tyr3-Octreotate (Lutathera) and Nivolumab for Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Rapid Kit-Based 68Ga-Labelling and PET Imaging With THP-Tyr3-octreotate: A Preliminary Comparison With DOTA-Tyr3-octreotate

EJNMMI Research
Nuclear MedicineRadiologyImaging
2015English

Potential Biomarkers for Radiation-Induced Renal Toxicity Following 177Lu-Octreotate Administration in Mice

PLoS ONE
Multidisciplinary
2015English

Nephrotoxicity After PRRT With 177Lu-Dota-Octreotate

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2016English

Utilization of Gold Containing Nanomaterials for Targeted Radiotherapeutic and Diagnostic Applications

English

Differences in Biodistribution Between99mTc-Depreotide,111In-Dtpa-Octreotide, And177Lu-Dota-Tyr3-Octreotate in a Small Cell Lung Cancer Animal Model

Cancer Biotherapy and Radiopharmaceuticals
Nuclear MedicineRadiologyPharmacologyCancer ResearchOncologyImagingMedicine
2005English

The Potential of Targeted Antiangiogenesis Therapies in the Treatment of Esophageal Cancer

Gastrointestinal Cancer: Targets and Therapy
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy